Evidence map›Paper›PMID 40546313›Full record

ArticleMolecular therapy. Oncology2025

Identification of dynamic network biomarker

Xuerong Gu, Qiwen Huang, Yucheng Huang, Dandan Ding, Jiayuan Zhong, Shengming Lin, Yingxin Yu, Hui Wang, Chang Liu, Pei Chen and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Xuerong GuSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, Guangdong 510641, China.
Qiwen HuangSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, Guangdong 510641, China.
Yucheng HuangDepartment of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong 519041, China.
Dandan DingFirst People's Hospital of Foshan, Sun Yat-sen University, Foshan, Guangdong 528000, China.
Jiayuan ZhongSchool of Mathematics and Big Data, Foshan University, Foshan, Guangdong 528000, China.
Shengming LinUniversity of Illinois at Chicago, Chicago, IL 60607, USA.
Yingxin YuSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, Guangdong 510641, China.
Hui WangSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, Guangdong 510641, China.
Chang LiuSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, Guangdong 510641, China.
Pei ChenSchool of Mathematics, South China University of Technology, Guangzhou, Guangdong 510641, China.
Chunbo ChenDepartment of Critical Care Medicine, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen 518020, China.
Wei LuoFirst People's Hospital of Foshan, Sun Yat-sen University, Foshan, Guangdong 528000, China.
Haiyu ZhouDepartment of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong 519041, China.
Rui LiuSchool of Mathematics, South China University of Technology, Guangzhou, Guangdong 510641, China.
Fei LingSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, Guangdong 510641, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acquired erlotinib resistance is the primary cause of treatment failure in patients with non-small cell lung cancer (NSCLC). Most current research focuses on end-stage resistance, whereas early events leading to resistance have been largely overlooked. In this study, we developed a novel dynamic network biomarker (DNB) method called single-cell differential covariance entropy (scDCE) to identify the pre-resistance state and associated DNB genes. We identified the DNB core gene

Indexed as

dynamic network biomarkerITGB1MT: Regular Issuenon-small cell lung cancerpre-resistance statesingle-cell differential covariance entropytrametinib

Identifiers

PMID40546313
PMCPMC12179664

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.